Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EGFR mutation

AstraZeneca AZ

AZ’s immuno-oncology combo fails another lung cancer trial

Latest failure casts doubt on company’s CTLA4 drug

- PMLiVE

Merck’s Keytruda meets survival challenge in NSCLC

Data showed that almost 70% of patients on the combo were still alive after 12 months

- PMLiVE

AZ makes case for first-line Tagrisso therapy in lung cancer

Data shows the drug improved PFS versus older EGFR inhibitors including Roche’s Tarceva

- PMLiVE

Merck’s Keytruda scores in frontline lung cancer yet again

Drug improved overall survival as a monotherapy, which rival BMS’ Opdivo was unable to show

- PMLiVE

Incyte/Merck trial failure bodes ill for IDO class

The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone

- PMLiVE

Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

Both EU and US regulatory advisors are currently assessing the drug

How scenario testing helped assess demand for a brand launch in the fragmented NSCLC market

Our client was developing a new drug aimed at first line NSCLC patients. Ahead of its launch they wanted to assess likely uptake in an already fragmented market space led...

Research Partnership

Roche Basel Switzerland

Another Tecentriq win for Roche as Avastin combo boosts survival

The Swiss pharma group reported a 38% improvement in PFS in NSCLC patients

- PMLiVE

New data could put Roche’s Tecentriq first in squamous lung cancer

NSCLC patients on the drug saw a reduced risk of disease progression

AstraZeneca AZ

AZ pushes back data read-out from MYSTIC lung cancer trial

The delay could further undermine confidence in a positive outcome

- PMLiVE

AZ adds another Ionis drug in $330m kidney disease deal

The candidate targets a genetically associated form of the condition

AstraZeneca AZ

AZ bags key lung cancer approval for Imfinzi

Becomes the first PD-1/PD-L1 inhibitor approved to treat inoperable stage III NSCLC patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links